Volume 8, Supplement 2, Jul-Aug-Sep 2011
Volume 5, Supplement 1, September-October 2008
A round table meeting for practice nurses: 7 July 2008, London
Volume 4, Supplement 1, May-June 2007
Volume 7, Supplement 2, Jul-Aug-Sep 2010
The new NICE guideline enables us to individualise care bearing in mind the needs of the person in front of us. It is concerned with clinical efficacy, and – for once – the cost of care has not noticeably influenced its recommendations. In contrast, QOF does the exact opposite, demanding that we drive our patients’ HbA1c down to low […]
The number of deaths each year from cardiovascular disease (CVD) has nearly halved in the UK since the early 1980s. There are many reasons for this success, but 25%-50% of the decline in deaths from coronary heart disease (CHD) can be attributed to secondary prevention in high-risk patients. However, despite the hard work of GPs […]
Despite the availability of effective therapies, there remains poor awareness, diagnosis and management of hypertension across the globe. Effective treatment requires an understanding of the underlying disease processes involved in hypertension which includes chronic increased sympathetic activity and peripheral resistance rather than focusing simply on blood pressure reduction. The differing pathophysiological response patterns of younger […]
A practical guide for primary care. If we wanted to make things simple, all patients with atrial fibrillation (AF) would receive an oral anticoagulant to reduce their risk of stroke and other comorbidities. But historically this has been difficult because anticoagulants can cause bleeding. Decisions about oral anticoagulation in patients with AF are therefore complex, […]
This supplement is sponsored by HRA Pharma, on behalf of whom the Expert Working Group was convened and funded. Editorial control has remained with the authors and the journal at all times. HRA Pharma reviewed the text for regulatory accuracy just prior to printing.
High blood pressure is undoubtedly the major modifiable risk factor for cardiovascular disease (CVD). However, despite advances in management, it remains inadequately managed. Across Europe, only about one in four of treated patients achieve guideline-recommended targets for blood pressure. This has important consequences for increasing the risk of CVD, kidney disease, microvascular disease, as well […]
This supplement was originally published in 2011 and has since been updated and peer-reviewed in January 2012.
This supplement is supported by Consilient Health Ltd on behalf of whom this Expert Working Group was convened and funded. Consilient Health Ltd also provided a framework for the discussion.